Secondary Prophylaxis in Non-Hodgkin Lymphoma (NHL) and Chemotherapy-induced Thrombocytopenia

PHASE2CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions
Non-Hodgkin Lymphoma
Interventions
DRUG

Romiplostim

"Romiplostim will be administered subcutaneously at a dose of 250 μg on the 1st, 3rd and 5th days after the last day of chemotherapy delivery and, then, every two days until the achievement of 75.000 plt/μL.~In the case of unsuccessful use of romiplostim after the second chemotherapy course, dose escalation to 500 μg/day, with the same above-mentioned schedule, will be indicated after the third course and for all the further courses, with a maximum of 8."

Trial Locations (1)

Unknown

Dip. Oncoematologia - Fondazione Centro San Raffaele del Monte Tabor, Milan

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

Andres J. M. Ferreri

OTHER